Tocilizumab role in reducing the complications of COVID patients

Tocilizumab role in reducing the complications of COVID patients - TOCIPAK Tocilizumab in Pakistan

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

REBEC

Registry ID

RBR-25rtydq

Enrollment

Unknown

Registered

2021-08-11

Start date

2020-04-16

Completion date

Unknown

Last updated

2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pneumonia due to COVID-19

Interventions

Single Arm Study: 59 patients admitted for the treatment of COVID-19 patients receive tocilizumab as a dose of 400 mg intravenously in 100 mL NaCl 0.9 % administered in 60 minutes as intervention. Co

D26.670

Eligibility

Age

17 Years to No maximum

Inclusion criteria

Inclusion criteria: Confirmed or suspected SARS-CoV infection; Adult patient; Moderate to Critical COVID Patients

Exclusion criteria

Exclusion criteria: Known hypersensitivity to Tocilizumab or its excipients; patient below 18 years; mild cases of Confirmed or suspected SARS-CoV

Design outcomes

Primary

Measure	Time frame
Rate of mortality in patients receiving tocilizumab in the hospital, verified by chi square test, it was observed that patients receiving invasive respiratory support were identified to higher risk of mortality than patients receiving oxygen support ( (50 vs 86, p<0.05)	—

Secondary

Measure	Time frame
Secondary outcomes are not expected	—

Countries

Pakistan

Contacts

Public ContactMuhammad Amir

mohd_amir80@hotmail.com++92-334-3266804

Outcome results

None listed

Source: REBEC (via WHO ICTRP) · Data processed: Feb 16, 2026